# Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma

> **NCT00012350** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 44 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** FTI

## Key facts

- **NCT ID:** NCT00012350
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2003-09
- **Final completion:** 2010-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-10-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00012350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00012350, "Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00012350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*